Hazel Urwin,Keith A. Josephs,Jonathan D. Rohrer,Ian R. Mackenzie,Manuela Neumann,Astrid Authier,Harro Seelaar,John C. Van Swieten,Jeremy M. Brown,Peter Johannsen,Jorgen E. Nielsen,Ida E. Holm,The FReJA Consortium,Dennis W. Dickson,Rosa Rademakers,Neill R. Graff-Radford,Joseph E. Parisi,Ronald C. Petersen,Kimmo J. Hatanpaa,Charles L. White III,Myron F. Weiner,Felix Geser,Vivianna M. Van Deerlin,John Q. Trojanowski,Bruce L. Miller,William W. Seeley,Julie van der Zee,Samir Kumar-Singh,Sebastiaan Engelborghs,Peter P. De Deyn,Christine Van Broeckhoven,Eileen H. Bigio,Han-Xiang Deng,Glenda M. Halliday,Jillian J. Kril,David G. Munoz,David M. Mann,Stuart M. Pickering-Brown,Valerie Doodeman,Gary Adamson,Shabnam Ghazi-Noori,Elizabeth M. C. Fisher,Janice L. Holton,Tamas Revesz,Martin N. Rossor,John Collinge,Simon Mead,Adrian M. Isaacs

Abstract:Through an international consortium, we have collected 37 tau- and TAR DNA-binding protein 43 (TDP-43)-negative frontotemporal lobar degeneration (FTLD) cases, and present here the first comprehensive analysis of these cases in terms of neuropathology, genetics, demographics and clinical data. 92% (34/37) had fused in sarcoma (FUS) protein pathology, indicating that FTLD-FUS is an important FTLD subtype. This FTLD-FUS collection specifically focussed on aFTLD-U cases, one of three recently defined subtypes of FTLD-FUS. The aFTLD-U subtype of FTLD-FUS is characterised clinically by behavioural variant frontotemporal dementia (bvFTD) and has a particularly young age of onset with a mean of 41 years. Further, this subtype had a high prevalence of psychotic symptoms (36% of cases) and low prevalence of motor symptoms (3% of cases). We did not find FUS mutations in any aFTLD-U case. To date, the only subtype of cases reported to have ubiquitin-positive but tau-, TDP-43- and FUS-negative pathology, termed FTLD-UPS, is the result of charged multivesicular body protein 2B gene ( CHMP2B ) mutation. We identified three FTLD-UPS cases, which are negative for CHMP2B mutation, suggesting that the full complement of FTLD pathologies is yet to be elucidated.

FUS Pathology Defines the Majority of Tau- and TDP-43-negative Frontotemporal Lobar Degeneration